Regulation 3.	Laboratory Reporting
Cases of diseases listed in Regulation 1 shall also be reported with the information required in Regulation 1 by laboratories whether or not associated with a hospital, and by out of state laboratories that maintain an office or collection facility in Colorado or arrange for collection of specimens in Colorado.  For test results required to be reported by laboratories in Regulation 3 that are not listed in Regulation 1, unless the information or timeframe for reporting is otherwise specified, the laboratory shall report within 7 days the patient's name, date of birth, sex, race, ethnicity, and address (including city and county); the name and address of responsible physician; and such other information as is needed to locate the patient for follow-up.  Results must be reported by the laboratory which performs the test, but an in-state laboratory which sends specimens to an out-of-state laboratory referral laboratory is also responsible for reporting results.  A case shall be reported by a laboratory when a result diagnostic of or highly correlated with clinical illness is found for any of the following organisms or diseases.  Test results indicating acute infection or chronic infectiousness for any of the following should be reported.  Laboratory assays which demonstrate only immunity should not be reported (for example, a single elevated rubella antibody titer obtained during routine prenatal screening should not be reported).

Bacillus anthracis	Neisseria gonorrhoeae	
Bordetella pertussis	Plasmodium species	
Borrelia burgdorferi	Poliomyelitis	
Brucella species	Q Fever	
Campylobacter species	Rabies	
Chlamydia psittaci	Relapsing Fever (Borrelia species)	
Chlamydia trachomatis	Rocky Mountain Spotted Fever	
Clostridium botulinum	Rubella (acute infection)	
Corynebacterium diphtheriae	Severe Acute Respiratory Syndrome (SARS)	
Cryptosporidium species	St. Louis encephalitis	
Cyclospora	Salmonella species, including typhi	
Escherichia coli 0157:H7** and shiga toxin-producing Escherichia coli	Shigella species	
Francisella tularensis	Smallpox	
Giardia lamblia	Treponema pallidum	
Haemophilus ducreyi	Vancomycin resistant Staphylococcus aureus, any site	
Hantavirus	Varicella	
Legionella species	Vibrio cholerae	
Listeria monocytogenes	Vibrios, non-cholera	
Measles (acute infection)	Western equine encephalitis	
Mumps	West Nile virus (acute infection)	
Mycobacterium tuberculosis, including antimicrobial sensitivity test results and positive AFB sputum smears.	Yersinia pestis	
	Yersinia, non-pestis +	
In addition to the above list, a laboratory shall report a case when any of the following specific laboratory results are found:
Group A streptococci – positive culture from a normally sterile site*
Group B streptococci - positive culture from a normally sterile site*
Methicillin resistant Staphylococcus aureus (MRSA) – positive culture from a normally sterile site (30 day timeframe for reporting)*
Clostridium difficile – any positive test (30 day timeframe for reporting)*
Haemophilus influenzae - positive culture from a normally sterile site
Hepatitis A - positive IgM anti-HAV
Hepatitis B - positive HBsAg, IgM anti-HBc, HBeAg, or HBV DNA
Hepatitis C - positive antibody titer or more specific tests
Neisseria meningitidis - positive culture from a normally sterile site
Streptococcus pneumoniae – positive culture from a normally sterile site
*  Condition reportable only in the Denver Metropolitan Area (Adams, Arapahoe, Denver, Douglas, and Jefferson Counties.)
+  Condition reportable only in the 7 county Denver Metropolitan Area (Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas, and Jefferson Counties.)
**  This includes any shiga-toxin test or O157 antigen test that is positive, even if no culture is performed. If the laboratory does not have the capacity to perform H (flagellar) antigen tests, then Escherichia coli 0157 should be reported.
Reference laboratories that receive specimens from other laboratories shall report results separately for each submitting facility.  The state or local health department may have access to pertinent, relevant medical and epidemiologic information about the individuals from whom cultures were collected in order to investigate drug-resistant communicable diseases and to develop and evaluate strategies to control the spread of these diseases.